We hereby submit details for Annual General Meeting of the Company. Kindly take the same on your records.
AMBALALSA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Ambalal Sarabhai Enterprises reported FY2025-26 consolidated revenue of Rs. 20,227 Lakhs, up 3.1% YoY from Rs. 19,619 Lakhs. Consolidated PAT surged to Rs. 1,780 Lakhs versus Rs. 493 Lakhs prior year—a 261% jump driven by higher segment profitability (Pharma Rs. 1,315 Lakhs, Electronics Rs. 1,026 Lakhs) and reduced exceptional items (Rs. 82 Lakhs vs Rs. 700 Lakhs). The Board approved inter-corporate loans to three subsidiaries (Asence Pharma, Synbiotics, Systronics India), reappointed three key executive directors (Kartikeya V. Sarabhai as Executive Chairman, Ms. Chaula M. Shastri as Whole-time Director, Mr. Mohal K. Sarabhai as Managing Director), and continued Mr. Govindprasad Namdeo as Independent Director beyond age 75. The 48th AGM is scheduled for July 30, 2026 via VC. Statutory auditors issued unqualified opinions on both standalone and consolidated results.
Strong bottom-line recovery with PAT growth over 261% and positive operating cash flow of Rs. 1,340 Lakhs signals improved operational efficiency, though modest 3% revenue growth suggests underlying business expansion is gradual.